NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDTofacitinib Xeljanz®
(Tablets) 		Musculoskeletal and joint diseases, Drugs which suppress the rheumatic disease process, 10.01.03
REDTofacitinib 5mg, 10mg Xeljanz®
(Tablets) 		Gastro-intestinal system, Drugs affecting the immune response, 01.05.03
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Tofacitinib Tofacitinib Gastro-Intestinal System, Chronic Bowel Disorders, Inflammatory Bowel Disease, Immunosuppressants JAK Inhibitors
Tofacitinib Tofacitinib Musculoskeletal System, Arthritis, Immunosuppressants JAK Inhibitors
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
MHRA DSU March 2020: Tofacitinib (Xeljanz): new measures to minimise risk of venous thromboembolism and of serious and fatal infections
MHRA DSU Oct 2021: Tofacitinib new measures to minimise risk of major adverse cardiovascular events and malignancies
NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
NICE TA735 Tofacitinib for treating juvenile idiopathic arthritis
NICE TA920: Tofacitinib for treating active ankylosing spondylitis